Breast Cancer

Posted: May 8, 2012 in Uncategorized
Tags:

An Army doctor has helped develop a vaccine that he believes will prevent cancer, or at least its recurrence. The drug NeuVax began phase III clinical trials 20 JAN which Col. George Peoples said could lead to its Food and Drug Administration approval. Peoples is chief of surgical oncology at the San Antonio Military Medical Center when he's not traveling the world to provide surgical expertise or working to try and find a cure for cancer. The phase III clinical trial for NeuVax will involve at least 700 breast cancer patients at 100 sites in the United States and abroad. The trial is titled PRESENT, Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment. Participants will receive one intradermal injection every month for six months, followed by a booster inoculation every six months thereafter. The primary endpoint is disease-free survival at three years. "The first patient was vaccinated with NeuVax in January at San Antonio Military Medical Center, Fort Sam Houston, Texas," Peoples said.
Peoples is the director and principal investigator for a Cancer Vaccine Development Program that he has been working on since the early 90s. The vaccine carries the generic name E75. This third and final phase of testing before FDA approval will bring NeuVax one step closer to the market and to the breast cancer patients who need more options, Peoples said. According to the Centers for Disease Control and Prevention, about 203,000 individuals in the United States are diagnosed with invasive breast cancer each year. The current vaccine is the result of nearly 20 years of research by Peoples and others, and has paralleled the development of the drug Herceptin. "Herceptin is one of our biggest breast cancer drugs right now. It targets a protein commonly over-expressed in breast cancer cells called human epidermal growth factor receptor 2, or HER2/neu. This drug has cut the rate of breast cancer recurrence in half ; the first drug to ever have this dramatic of a response. "So of course, HER2/neu became the molecule of the decade and Herceptin now is a multi-billion dollar drug," Peoples said. [Source: U.S Army Homepage Rob McIlvaine article http://www.army.mil/article/78062/Army_surgeon_on_track_to_head_off_cancer_before_it_starts/ 18 Apr 2012 ++]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s